1-(4-chlorophenyl)-1-cyclohexanecarboxylic acid methyl ester | 51275-34-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-chlorophenyl)-1-cyclohexanecarboxylic acid methyl ester
• 英文别名: methyl 1-(4-chlorophenyl)cyclohexanecarboxylate；methyl 1-(4-chlorophenyl)cyclohexane-1-carboxylate
• CAS: 51275-34-4
• 化学式: C₁₄H₁₇ClO₂
• 分子量: 252.741
• InChiKey: SHDCRBFNUMCGRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-chlorophenyl)-1-cyclohexanecarboxylic acid methyl ester 在 肼 作用下， 以 乙二醇 为溶剂， 反应 15.0h， 生成 1-(4-chlorophenyl)cyclohexanecarbohydrazide
  参考文献：
  名称：

  [EN] 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA
  [FR] INHIBITEURS DE LA 11-BETA-HYDROXYSTEROIDE DESHYDROGENASE 1 UTILISABLES POUR LE TRAITEMENT DU DIABETE, DE L'OBESITE ET DE LA DYSLIPIDEMIE

  摘要：

  公开号：

  WO2003104207A3
• 作为产物：
  描述：

  重氮甲烷 、 1-(4-氯苯基)环己烷-1-羧酸 以 乙醚 为溶剂， 反应 24.0h， 以98%的产率得到1-(4-chlorophenyl)-1-cyclohexanecarboxylic acid methyl ester
  参考文献：
  名称：

  Design and synthesis of novel imidazoline derivatives with potent antihyperglycemic activity in a rat model of type 2 diabetes

  摘要：

  Imidazoline derivatives have been reported to show anti hyperglycemic activity in vivo. In the present study, we first showed that there was no correlation between the in vivo antidiabetic activity and the in vitro affinities for the I-1/I-2 binding sites for several substituted daryl imidazolines. Among these compounds, 2-(alpha-cyclohexyl-benzyl)-4,5-dihydro-1H-imidazole 2 exhibited potent antihyperglycemic properties. It was then chosen as lead compound. Thirty-six new derivatives were synthesized by replacing the cyclohexyl/benzyl group by various cyclic systems or the imidazoline ring by isosteric heterocycles. These compounds were evaluated in vivo for their antihyperglycemic activity using an oral glucose tolerance test (OGTT) in a rat model of type-2 diabetes obtained by giving a single intravenous (iv) injection of a low dose of streptozotocin to rats (STZ rats) and in normal rats. Nine compounds with an imidazoline moiety, possibly substituted by a methyl group, had a potent effect on the glucose tolerance in normal or STZ-diabetic rats, after an oral (po) administration of the test compound at a dose of 30 or 10 mg kg(-1) without any hypoglycemia. Replacement of the imidazoline ring by isosteric heterocycles resulted in a total loss of activity. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.07.026

文献信息

• 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
  申请人：——

  公开号：US20040106664A1

  公开（公告）日：2004-06-03

  Compounds having Formula I, including pharmaceutically acceptable salts, hydrates and solvates thereof: 1 are selective inhibitors of the 11&bgr;-HSD1 enzyme. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dylsipidernia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM.

  具有I式的化合物，包括药物可接受的盐、水合物和溶剂化合物：1是11&bgr;-HSD1酶的选择性抑制剂。这些化合物可用于治疗糖尿病，如非胰岛素依赖性糖尿病（NIDDM），高血糖，肥胖症，胰岛素抵抗，血脂异常，高脂血症，高血压，X综合征以及与NIDDM相关的其他症状。
• 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA
  申请人：——

  公开号：US20040048912A1

  公开（公告）日：2004-03-11

  Compounds having Formula I, including pharmaceutically acceptable salts, hydrates and solvates thereof: 1 are selective inhibitors of the 11&bgr;-HSD1 enzyme. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dylsipidemia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM.

  式I的化合物，包括药学上可接受的盐、水合物和溶剂化物：1是11β-HSD1酶的选择性抑制剂。这些化合物可用于治疗糖尿病，如非胰岛素依赖性糖尿病（NIDDM）、高血糖、肥胖症、胰岛素抵抗、脂质代谢紊乱、高脂血症、高血压、X综合症以及与NIDDM相关的其他症状。
• 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1532122B1

  公开（公告）日：2011-12-14
• US6730690B2
  申请人：——

  公开号：US6730690B2

  公开（公告）日：2004-05-04
• US7179802B2
  申请人：——

  公开号：US7179802B2

  公开（公告）日：2007-02-20